Inhibrx claims first win for long-sought immunotherapy target
Inhibrx reports that its drug INBRX-106 nearly doubles response rates and achieves an interim median progression-free survival of 9.6 months in a Phase 2 head and neck squamous cell carcinoma study. The company claims this milestone represents the first clinical win for a long-sought immunotherapy target involving an OX40 agonist. The chief executive officer states that the progression-free survival data leave no question about the durability of the treatment, while also opening the door for potential cancer vaccine combinations.
Listen to Live Briefing
Real-time synthesized voice briefing · Live Feeds Desk
- ✓ Inhibrx reports its INBRX-106 therapy nearly doubled response rates and achieved an interim median progression-free survival of 9.6 months in a Phase 2 HNSCC study.
- ✓ The company claims the milestone represents the first clinical win for a long-sought immunotherapy target using an OX40 agonist.
- ✓ An Inhibrx director purchased 2,500 shares via a family trust.
- ✓ H.C. Wainwright reiterated its buy rating on Inhibrx Biosciences stock.
What changed
Inhibrx released Phase 2 data for its INBRX-106 treatment demonstrating a near-doubling of response rates and an interim median progression-free survival of 9.6 months in head and neck squamous cell carcinoma.
Live updates
-
Inhibrx Claims First Win for Long-Sought Immunotherapy Target
Inhibrx reports that its drug INBRX-106 nearly doubles response rates and achieves an interim median progression-free survival of 9.6 months in a Phase 2 head and neck squamous cell carcinoma study. The company claims this milestone represents the first clinical win for a long-sought immunotherapy target involving an OX40 agonist. The chief executive officer states that the progression-free survival data leave no question about the durability of the treatment, while also opening the door for potential cancer vaccine combinations.
Why it matters
Targeting OX40 has long been sought in immunotherapy, but previous industry efforts have struggled to generate clear clinical wins. Demonstrating durability in progression-free survival marks a significant shift for this mechanism in cancer treatment. The positive data have drawn attention from financial analysts, prompting reiterations of buy ratings and prompting an insider stock purchase.
What is confirmed
- Inhibrx reports its INBRX-106 therapy nearly doubled response rates and achieved an interim median progression-free survival of 9.6 months in a Phase 2 HNSCC study.
- The company claims the milestone represents the first clinical win for a long-sought immunotherapy target using an OX40 agonist.
- An Inhibrx director purchased 2,500 shares via a family trust.
- H.C. Wainwright reiterated its buy rating on Inhibrx Biosciences stock.
Still unconfirmed
- Inhibrx cancer therapy outperforms Merck’s Keytruda.
What to watch next
- Further clinical data on combination therapies involving the OX40 agonist and cancer vaccines
- Additional trial updates regarding INBRX-106 in Phase 2 studies
confidence 100%Sources used for this update (8)
- STAT — Inhibrx claims first win for long-sought immunotherapy target
- Fierce Biotech — Inhibrx CEO says progression-free survival data leave ‘no question’ about OX40 agonist’s durability
- Endpoints News — Inhibrx opens door to cancer vaccine combo for its OX40 agonist
- newswise.com — Inhibrx's INBRX-106 Nearly Doubles Response Rate and Achieves Interim Median PFS of 9.6 months in Phase 2 HNSCC Study | Newswise
- stocktitan.net — Inhibrx (INBX) director buys 2,500 shares via family trust
- PR Newswire — Inhibrx's INBRX-106 Nearly Doubles Response Rate and Achieves Interim Median PFS of 9.6 months in Phase 2 HNSCC Study
- Seeking Alpha — Inhibrx cancer therapy outperforms Merck’s Keytruda (INBX:NASDAQ)
- Investing.com — H.C. Wainwright reiterates Inhibrx Biosciences stock rating at buy
Community Sentiment: How do you assess this situation?
Voice your perspective · Real-time aggregated sentiment from the Live Feeds community